 - Chronic lymphocytic leukemia CLL: must have failed 2 lines of conventional therapy and must be refractory to fludarabine; this includes patients who fail to have a complete or partial response after therapy with a regimen containing fludarabine or another nucleoside analog or experience disease relapse within 12 months after completing therapy with a regimen containing fludarabine or another nucleoside analog; 